港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

恒瑞医药

77.150

-0.800-1.03%

成交量：121.34万

成交额：9,371.67万

市值：5,120.45亿

市盈率：70.69

高：78.500

开：78.500

低：76.550

收：77.950

52周最高：87.800

52周最低：52.500

股本：66.37亿

香港流通股本：2.58亿

量比：0.44

换手率：0.47%

股息：0.22

股息率：0.28%

每股收益(LYR):1.091

净资产收益率：14.41%

总资产收益率：8.45%

市净率：8.03

市盈率(LYR):70.69

市销率: 15.56

数据加载中...

总览公司新闻公告

累计研发投入近500亿后，恒瑞医药上半年业绩迎来“爆发”

恒瑞医药(01276.HK)：HRS-2162注射液获药物临床试验批准通知书

恒瑞医药(01276)收到国家药监局核准签发关于HRS-6093片的《药物临床试验批准通知书》

智通AH统计|8月25日

【券商聚焦】交银国际首予恒瑞医药(01276)港股中性评级指管线进入集中收获期

恒瑞医药(01276)中报观：创新药内生增长动能凸显，持股计划解锁目标彰显创新药发展信心

恒瑞医药：出海扬帆，创新为王

恒瑞医药(1276.HK)获纳入恒生综合指数

智通AH统计|8月22日

大行评级｜美银：上调恒瑞医药A股目标价至60元上调2026/2027年盈利预测

营收、净利创新高！恒瑞医药的中报有哪些看点？

群益证券给予恒瑞医药买进评级，主业稳步增长，BD收益增厚利润，25H1净利YOY+30%

每日经济新闻

港股开盘 | 恒指高开0.2% 创新药概念集体高开恒瑞医药(01276)绩后涨超1%

智通财经网

盘前公告淘金：牧原股份业绩炸裂！上半年净利润暴增11倍；恒瑞医药拟以10亿元-20亿元回购股份

恒瑞医药(01276.HK)拟回购10亿-20亿元A股股份

恒瑞医药(01276.HK)拟使用不超60亿元自有闲置资金进行委托理财

恒瑞医药上半年营收同比增长16%，净利润增近30%，创新药收入达75.7亿元

华尔街见闻

恒瑞医药(01276.HK)创新药销售引领业绩增长上半年归母净利为44.5亿元同比增长29.7%

恒瑞医药(01276)建议采纳2025年A股员工持股计划

恒瑞医药(01276.HK)2025年半年报：营收、净利双创新高，业绩强势增长

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/01276/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":77.15,"timestamp":1756178640736,"preClose":77.95,"halted":0,"volume":1213400,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.0913471676598538,"marketStatus":"交易中","change":-0.8,"latestTime":"08-26 11:24:23","open":78.5,"high":78.5,"low":76.55,"amount":93716720,"amplitude":0.025016,"askPrice":77.15,"askSize":15000,"bidPrice":77.05,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":1.2665193015409368,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1756180800000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":77.95,"dividendRate":0.002836,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.444006,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":65.56,"timestamp":1756178660000,"preClose":66.26,"halted":0,"volume":33566300,"delay":0,"premium":"+7.83"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.45%","roe":"14.41%","lyrEps":1.091347,"volumeRatio":0.444006,"shares":6637000000,"dividePrice":0.218269,"high":78.5,"amplitude":0.025016,"preClose":77.95,"low":76.55,"week52Low":52.5,"pbRate":"8.03","psRate":"15.56","week52High":87.8,"institutionHeld":0,"latestPrice":77.15,"committee":-0.851852,"eps":1.0913471676598538,"divideRate":0.002829,"volume":1213400,"delay":0,"ttmEps":1.2665193015409368,"open":78.5,"prevYearClose":44.05,"prevWeekClose":76.4,"prevMonthClose":78.85,"prevQuarterClose":53.8,"fiveDayClose":79,"twentyDayClose":81.8,"sixtyDayClose":57.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2609,"buy":0.5217,"hold":0.1739,"sell":0.0435,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5217,"analysts":23,"updateTime":1753891200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-08-25","current":59.937003,"percent":0.787879,"low":50.027905,"twenty":51.588838,"median":54.897923,"eighty":60.114857,"high":62.321749,"avg":55.377377,"sd":4.031887,"marketCap":481561599281},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-25","current":59.937003,"twenty":51.588838,"median":54.897923,"eighty":60.114857,"marketCap":481561599281}],"updateTime":1756176916374},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562228366","title":"累计研发投入近500亿后，恒瑞医药上半年业绩迎来“爆发”","url":"https://stock-news.laohu8.com/highlight/detail?id=2562228366","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562228366?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:31","pubTimestamp":1756128660,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　来源 | 野马财经。　　8月20日，国内创新药龙头企业恒瑞医药发布2025年上半年财报。　　营收、净利及经营性现金流净额均创往年同期新高，业绩进入爆发增长期。　　分业务来看，上半年创新药销售及许可贡献收入95.61亿元，占营收比重达60.66%；其中，创新药销售收入达75.7亿元，占药品销售收入比重达55.3%。截至上半年末，恒瑞医药累计的研发投入已经超过480亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-08-25/doc-infnfiev3613284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","LU0359201885.HKD","LU1997244956.HKD","LU1328615791.USD","LU1064131003.USD","LU2495084118.USD","01276","BK0012","LU0359202008.SGD","BK0196","LU1997245177.USD","BK0028","BK0239","LU1064130708.USD","LU2488822045.USD","LU0359201612.USD","LU0405327494.USD","LU2543165471.USD","LU1997245094.SGD","LU1655091616.SGD","LU1969619763.USD","LU2328871848.SGD","BK0183","LU1023057109.AUD","600276","LU2580892789.USD","LU0405327148.USD","LU1255011170.USD","BK0060","LU2580892862.HKD","LU2148510915.USD","BK0188"],"gpt_icon":0},{"id":"2562175242","title":"恒瑞医药(01276.HK)：HRS-2162注射液获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2562175242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562175242?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 17:29","pubTimestamp":1756114197,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1328615791.USD","159938","BK1191","LU2543165471.USD","LU1997245094.SGD","BK0196","LU1997245177.USD","600276","BK0183","LU0359201885.HKD","01276","LU0405327148.USD","LU0405327494.USD","BK0188","BK1574","LU1064130708.USD","LU2488822045.USD","BK0239","LU1064131003.USD","LU0359201612.USD","BK1161","LU1255011170.USD","LU2328871848.SGD","09939","LU2495084118.USD","BK0028","BK1515","LU2148510915.USD","BK0012","BK0060","LU1655091616.SGD","LU1997244956.HKD","LU1023057109.AUD","LU0359202008.SGD","LU1969619763.USD","LU2580892789.USD","LU2580892862.HKD"],"gpt_icon":0},{"id":"2562127582","title":"恒瑞医药(01276)收到国家药监局核准签发关于HRS-6093片的《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2562127582","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562127582?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 17:23","pubTimestamp":1756113811,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，公司收到国家药品监督管理局(“国家药监局”)核准签发关于HRS-6093片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-6093 片是一种新型、高效、选择性的口服KRAS G12D抑制剂，能够特异性结合KRAS G12D突变蛋白，发挥抗肿瘤作用。经查询，国内外尚无同类产品获批上市。截至目前，HRS-6093片相关项目累计研发投入约2984万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","LU0405327494.USD","LU1255011170.USD","BK0196","LU1328615791.USD","LU1997245094.SGD","LU1997245177.USD","LU2488822045.USD","LU0359201885.HKD","LU1969619763.USD","BK0188","LU2580892789.USD","LU2495084118.USD","LU2580892862.HKD","LU1023057109.AUD","LU1997244956.HKD","01276","LU0359202008.SGD","BK1191","LU2148510915.USD","BK0028","BK0183","BK0239","LU2328871848.SGD","LU1064131003.USD","LU0359201612.USD","LU2543165471.USD","BK0012","600276","BK0060","LU1064130708.USD","LU1655091616.SGD"],"gpt_icon":0},{"id":"2562211876","title":"智通AH统计|8月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2562211876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562211876?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 16:15","pubTimestamp":1756109705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止8月25日收盘，东北电气、弘业期货、安德利果汁分列AH溢价率前三位，溢价率分别为743.75%、241.98%、236.37%；宁德时代、恒瑞医药、美的集团分列AH溢价率末三位，溢价率分别为-16.43%、1.82%、4.90%。其中安德利果汁、金力永磁、京城机电股份的偏离值位居前三，分别为32.29%、22.19%、20.80%；另外，比亚迪股份、东北电气、龙蟠科技的偏离值位居后三，分别为-98.36%、-64.84%、-51.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02727","01108","02338","02465","BK1148","BYDDY","399300","LU0345780521.USD","01288","BK1509","01349","SG9999015945.SGD","00042","06680","BK1183","SG9999014674.SGD","01276","01618","002594","02603","01877","02238","02865","03968","06066","159982","01812","02218","81211","01456","03606","BK1584","00300","LU0084288322.USD","02899","06869","03750","01033","00916","LU0307460666.USD","02628","03143","LU1655091616.SGD","03678","00187","HYDD.SI","00568"],"gpt_icon":1},{"id":"2562761299","title":"【券商聚焦】交银国际首予恒瑞医药(01276)港股中性评级 指管线进入集中收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2562761299","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562761299?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 10:27","pubTimestamp":1756088853,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，根据恒瑞医药 港股公告，1H25收入同比增长16%，剔除合作收入后的产品销售收入增长约13%，主要得益于创新药销售的快速增长。考虑到公司当前估值合理、且长期内高BD收入可持续性和存量仿制药集采仍存在不确定性，该机构给予港股和A股中性评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1964716","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","HSTECH","YANG","HSCEI","600276"],"gpt_icon":1},{"id":"2561268795","title":"恒瑞医药(01276)中报观：创新药内生增长动能凸显，持股计划解锁目标彰显创新药发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2561268795","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561268795?lang=zh_cn&edition=fundamental","pubTime":"2025-08-24 19:32","pubTimestamp":1756035173,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药发布2025年半年度报告。而8月20日恒瑞医药的A股收盘价为62.85元。但实际上，恒瑞医药在A股年初至今的股价涨幅已超过40%。而报告期内，恒瑞医药还有6款1类创新药和6个新适应症获批上市，创新成果不断加速落地。小结本次恒瑞再次推出员工持股计划，且设定的三年期创新药收入增长指标复合增长率均保持在25%以上的高位，充分证明了公司对创新药业务持续高速增长的坚定信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU1255011170.USD","LU2543165471.USD","LU2495084118.USD","BK0012","LU1023057109.AUD","BK1161","LU2148510915.USD","600276","BK0028","06978","LU1997245094.SGD","LU1997244956.HKD","LU0359201612.USD","LU2580892862.HKD","BK1574","BK0239","LU0359202008.SGD","159992","LU1064131003.USD","LU1328615791.USD","LU2488822045.USD","BK0188","LU1997245177.USD","LU1969619763.USD","BK0183","LU1064130708.USD","LU0405327148.USD","LU2580892789.USD","LU0405327494.USD","BK0060","01276","BK1191","LU1655091616.SGD","BK0196","LU0359201885.HKD"],"gpt_icon":0},{"id":"2561254581","title":"恒瑞医药：出海扬帆，创新为王","url":"https://stock-news.laohu8.com/highlight/detail?id=2561254581","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561254581?lang=zh_cn&edition=fundamental","pubTime":"2025-08-24 13:03","pubTimestamp":1756011817,"startTime":"0","endTime":"0","summary":"中国创新药全球崛起浪潮中，恒瑞医药率先转型、持续引领，真正实现了从跟随到领跑的“破茧成蝶”！","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/138.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/138.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2711541","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["600276","LU1997245177.USD","LU2580892789.USD","BK0183","LU2328871848.SGD","LU1997245094.SGD","LU0359201612.USD","LU1064130708.USD","LU2580892862.HKD","BK0239","LU2148510915.USD","LU0359201885.HKD","LU0405327494.USD","LU2495084118.USD","BK0028","LU2488822045.USD","LU1023057109.AUD","01276","LU1255011170.USD","LU0359202008.SGD","LU1328615791.USD","LU1969619763.USD","BK0196","BK0012","LU1655091616.SGD","BK0060","BK1191","LU1064131003.USD","BK0188","LU0405327148.USD","LU2543165471.USD","LU1997244956.HKD"],"gpt_icon":0},{"id":"2561302251","title":"恒瑞医药(1276.HK)获纳入恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2561302251","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561302251?lang=zh_cn&edition=fundamental","pubTime":"2025-08-24 11:19","pubTimestamp":1756005599,"startTime":"0","endTime":"0","summary":"恒生指数公司8月22日晚宣布截至2025年6月30日的恒生指数系列季度检讨结果，其中，恒瑞医药(1276.HK)获纳入恒生综合指数，变动将于9月5日(星期五)收市后实施，并于9月8日(星期一)起生效。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/24111952653732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","HSCI","LU1064131003.USD","01276","LU0359201885.HKD","LU0405327494.USD","LU2488822045.USD","LU0359201612.USD","LU2148510915.USD","LU1997245177.USD","LU2328871848.SGD","BK0183","LU1997244956.HKD","600276","LU1655091616.SGD","LU2580892789.USD","LU1023057109.AUD","BK0239","BK0028","LU1328615791.USD","LU2543165471.USD","BK0012","LU1969619763.USD","LU0405327148.USD","LU2580892862.HKD","BK0188","LU1255011170.USD","LU2495084118.USD","BK0060","BK0196","LU1997245094.SGD","LU1064130708.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2561417421","title":"智通AH统计|8月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2561417421","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561417421?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 16:15","pubTimestamp":1755850507,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止8月22日收盘，东北电气、安德利果汁、弘业期货分列AH溢价率前三位，溢价率分别为757.14%、241.27%、236.23%；宁德时代、恒瑞医药、美的集团分列AH溢价率末三位，溢价率分别为-17.71%、0.88%、6.01%。其中安德利果汁、京城机电股份、凯盛新能的偏离值位居前三，分别为39.59%、28.23%、18.28%；另外，比亚迪股份、东北电气、龙蟠科技的偏离值位居后三，分别为-104.77%、-58.88%、-43.45%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1333449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02218","00300","02628","01276","01618","02039","03143","01658","IE0008369823.USD","02338","HYDD.SI","00042","01033","02465","01349","03606","GWLLY","01108","159982","01456","06869","01288","01812","601633","BK1149","06680","00916","00187","LU0348825331.USD","00568","02068","LU0231483743.USD","LU1675838814.USD","BYDDY","03968","81211","03750","02333","00358","02899","03678","LU0823039010.USD","01057","06066","399300","82333","002594"],"gpt_icon":1},{"id":"2561289314","title":"大行评级｜美银：上调恒瑞医药A股目标价至60元 上调2026/2027年盈利预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2561289314","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561289314?lang=zh_cn&edition=fundamental","pubTime":"2025-08-22 13:50","pubTimestamp":1755841813,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["600276","LU1997245177.USD","LU2580892789.USD","BK0183","LU2328871848.SGD","LU1997245094.SGD","LU0359201612.USD","LU1064130708.USD","LU2580892862.HKD","BK0239","LU2148510915.USD","LU0359201885.HKD","LU0405327494.USD","LU2495084118.USD","BK0028","LU2488822045.USD","LU1023057109.AUD","01276","LU1255011170.USD","LU0359202008.SGD","161027","LU1328615791.USD","LU1969619763.USD","BK0196","BK0012","LU1655091616.SGD","BK0060","BK1191","LU1064131003.USD","BK0188","LU0405327148.USD","159982","LU2543165471.USD","LU1997244956.HKD","399300"],"gpt_icon":0},{"id":"2561457924","title":"营收、净利创新高！恒瑞医药的中报有哪些看点？","url":"https://stock-news.laohu8.com/highlight/detail?id=2561457924","media":"财华社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561457924?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 16:23","pubTimestamp":1755764587,"startTime":"0","endTime":"0","summary":"近期，包括诺诚健华（09969.HK）、百济神州（06160.HK）、科伦博泰生物-B（06990.HK）在内的多家创新药企相继披露了2025年中期业绩相关消息。","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202508_1/b31952e6-8991-4116-87f2-7822bb9eab40.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202508_1/b31952e6-8991-4116-87f2-7822bb9eab40.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/68a6d76b2308298cc66dca01","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["01276"],"gpt_icon":0},{"id":"2561452843","title":"群益证券给予恒瑞医药买进评级，主业稳步增长，BD收益增厚利润，25H1净利YOY+30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561452843","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561452843?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 15:40","pubTimestamp":1755762014,"startTime":"0","endTime":"0","summary":"群益证券8月21日发布研报称，给予恒瑞医药（600276.SH，最新价：63.99元）买进评级。评级理由主要包括：1）主业创新收入驱动增长，BD交易收入将继续增厚下半年净利；2）A股员工持股计划及A股回购计划；3）盈利预计及投资建议。风险提示：新药研发进度及销售不及预期，授权兑现不及预期，汇兑损益风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508213490618825.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508213490618825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276"],"gpt_icon":0},{"id":"2561439514","title":"港股开盘 | 恒指高开0.2% 创新药概念集体高开 恒瑞医药(01276)绩后涨超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561439514","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561439514?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 09:27","pubTimestamp":1755739656,"startTime":"0","endTime":"0","summary":"恒生指数高开0.2%，恒生科技指数跌0.03%。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250821/20250821092835_99517.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250821/20250821092835_99517.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4614","LU1255011170.USD","LU0359202008.SGD","LU1997245094.SGD","LU1655091616.SGD","LU1969619763.USD","BK1161","HSCEI","BK1191","LU1328615791.USD","MCHmain","LU2488822045.USD","600276","BK0012","LU2580892789.USD","LU0359201885.HKD","06978","LU1064131003.USD","BK0060","BK0028","BK1574","LU2328871848.SGD","MHImain","513600","LU1023057109.AUD","HHImain","BK0239","159992","BK0188","02833","BK0196","LU0405327148.USD","LU1997244956.HKD","LU2543165471.USD","LU2148510915.USD","HSI","LU2580892862.HKD","LU1064130708.USD","LU0405327494.USD","LU0359201612.USD","YANG","LU1997245177.USD","HSImain","HSTECH","01276","LU2495084118.USD","BK0183"],"gpt_icon":1},{"id":"2561275433","title":"盘前公告淘金：牧原股份业绩炸裂！上半年净利润暴增11倍；恒瑞医药拟以10亿元-20亿元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2561275433","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561275433?lang=zh_cn&edition=fundamental","pubTime":"2025-08-21 08:15","pubTimestamp":1755735346,"startTime":"0","endTime":"0","summary":"【重要事项】万通发展：数渡科技的PCIe5.0交换芯片有望于25年底逐步开始批量供货仁和药业：ULook脑机交互智能眼镜目前在试销售验证阶段盈趣科技：拟定增募资不超8亿元 用于马来西亚智造基地扩建等项目恒誉环保：与英国某客户签署2758万美元销售合同智光电气：孙公司签订1.86亿元储能系统采购合同胜宏科技：向香港联交所递交H股发行并上市申请并刊发申请资料天味食品：筹划发行H股股票并在香港联交所上市","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.jrj.com.cn/2025/08/21081552578698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01276","600276","002714"],"gpt_icon":0},{"id":"2560910173","title":"恒瑞医药(01276.HK)拟回购10亿-20亿元A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2560910173","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560910173?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 21:11","pubTimestamp":1755695517,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023057109.AUD","01276","LU1064131003.USD","LU1997245177.USD","LU0359202008.SGD","BK0012","LU0359201612.USD","600276","159982","BK0239","LU2580892862.HKD","CNHmain","LU1655091616.SGD","BK0196","CYB","BK0028","LU2543165471.USD","BK1191","UCmain","LU0405327148.USD","LU1064130708.USD","LU2488822045.USD","LU1997244956.HKD","LU2148510915.USD","399300","LU2580892789.USD","BK0183","LU1255011170.USD","LU1969619763.USD","MUCmain","LU0405327494.USD","LU0359201885.HKD","LU2495084118.USD","LU1997245094.SGD","BK0060","MCNHmain","LU2328871848.SGD","LU1328615791.USD","BK0188"],"gpt_icon":0},{"id":"2560610606","title":"恒瑞医药(01276.HK)拟使用不超60亿元自有闲置资金进行委托理财","url":"https://stock-news.laohu8.com/highlight/detail?id=2560610606","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560610606?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 21:05","pubTimestamp":1755695118,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2495084118.USD","MUCmain","LU0405327148.USD","LU1997244956.HKD","BK0028","BK0188","LU2328871848.SGD","01276","BK0183","LU2148510915.USD","LU2580892789.USD","BK0196","LU0359201885.HKD","LU1969619763.USD","BK1191","LU1023057109.AUD","LU1064131003.USD","600276","CYB","BK0060","UCmain","LU2580892862.HKD","LU1255011170.USD","LU1064130708.USD","LU1997245094.SGD","LU0359201612.USD","LU1328615791.USD","LU2488822045.USD","CNHmain","LU1655091616.SGD","MCNHmain","LU1997245177.USD","BK0012","LU2543165471.USD","BK0239","LU0359202008.SGD","LU0405327494.USD"],"gpt_icon":0},{"id":"1168067873","title":"恒瑞医药上半年营收同比增长16%，净利润增近30%，创新药收入达75.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168067873","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168067873?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 20:25","pubTimestamp":1755692755,"startTime":"0","endTime":"0","summary":"恒瑞医药2025年上半年实现营业收入157.6亿元，同比增长15.88%，归母净利润44.5亿元，同比增长29.67%。业绩表现超预期，创新转型成效持续释放恒瑞医药2025年上半年交出了一份亮眼的成绩单。从收入结构看，创新药销售及许可收入达95.61亿元，占总收入比重高达60.66%，其中创新药销售收入75.70亿元。截至目前，公司已在中国获批上市23款新分子实体药物，创新成果稳居行业领先地位。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3753740","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3753740","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药上半年营收同比增长16%，净利润增近30%，创新药收入达75.7亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_api","symbols":["01276","600276"],"gpt_icon":1},{"id":"2560410557","title":"恒瑞医药(01276.HK)创新药销售引领业绩增长 上半年归母净利为44.5亿元 同比增长29.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560410557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560410557?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 20:21","pubTimestamp":1755692493,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1328615791.USD","LU0405327148.USD","LU0405327494.USD","BK0012","UCmain","LU1997244956.HKD","CNHmain","LU2543165471.USD","BK0188","BK1191","LU2328871848.SGD","LU1064131003.USD","LU1969619763.USD","LU2488822045.USD","LU1023057109.AUD","LU2495084118.USD","BK1161","LU0359202008.SGD","BK0183","LU0359201612.USD","BK0028","06978","600276","BK0060","01276","BK0239","BK1574","LU1064130708.USD","MUCmain","LU1255011170.USD","LU2580892789.USD","LU2580892862.HKD","LU1997245094.SGD","LU1997245177.USD","159992","LU0359201885.HKD","CYB","BK0196","LU2148510915.USD","MCNHmain","LU1655091616.SGD"],"gpt_icon":0},{"id":"2560610534","title":"恒瑞医药(01276)建议采纳2025年A股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2560610534","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560610534?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 20:20","pubTimestamp":1755692455,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，其已于2025年8月20日举行的董事会会议上审议通过了员工持股计划。员工持股计划有待公司股东会审议批准后方能生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1332364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","LU1997244956.HKD","01276","LU2580892789.USD","BK0196","LU0405327148.USD","LU1997245177.USD","600276","LU1997245094.SGD","LU0359201885.HKD","BK0028","LU1255011170.USD","LU2148510915.USD","BK0239","BK0188","399300","LU2580892862.HKD","LU1969619763.USD","LU2328871848.SGD","BK0060","LU0405327494.USD","LU2543165471.USD","LU1328615791.USD","LU1655091616.SGD","LU1064130708.USD","LU2495084118.USD","BK0183","LU0359201612.USD","BK0012","LU1023057109.AUD","LU1064131003.USD","LU0359202008.SGD","LU2488822045.USD","BK1191"],"gpt_icon":0},{"id":"2560108748","title":"恒瑞医药(01276.HK)2025年半年报：营收、净利双创新高，业绩强势增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2560108748","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560108748?lang=zh_cn&edition=fundamental","pubTime":"2025-08-20 19:48","pubTimestamp":1755690520,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023057109.AUD","BK0196","BK0028","BK0188","LU1997244956.HKD","LU2495084118.USD","LU1255011170.USD","LU1997245094.SGD","LU1969619763.USD","LU0359202008.SGD","LU1064131003.USD","LU1328615791.USD","LU2580892862.HKD","LU0359201885.HKD","LU2148510915.USD","BK0239","LU1655091616.SGD","BK0183","159399","BK0060","LU2488822045.USD","01276","LU1064130708.USD","BK1191","LU0359201612.USD","LU1997245177.USD","600276","LU2543165471.USD","LU0405327494.USD","LU0405327148.USD","BK0012","LU2580892789.USD","LU2328871848.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":1,"totalSize":380,"code":"91000000","status":"200"}]}}